Login to Your Account

StemCells: Spinal Injury Gains Are Sustained After One Year

By Catherine Shaffer
Staff Writer

Wednesday, February 13, 2013
StemCells Inc. reported positive results from the first patient cohort of a Phase I/II trial of its human neural stem cell product for spinal cord injury, and investors responded enthusiastically, driving the Newark, Calif.-based company's stock up 21 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription